Registrars: | Equiniti |
Brands: | Lucozade, Horlicks, Ribena, Paxil, Seroxat |
CEO: | Emma Walmsley |
Chief Finance Officer: | Julie Brown |
Independent Non-Executive Director: | Jesse Goodman |
Independent Non-Executive Director: | Vishal Sikka |
Independent Non-Executive Director: | Elizabeth (Liz) McKee Anderson |
Independent Non-Executive Director: | Anne Beal |
Independent Non-Executive Director: | Harry (Hal) C. Dietz |
Non-Executive Chairman: | Jonathan Symonds |
Senior Independent Non-Executive Director: | Charles Bancroft |
Non-Executive Dir: | Wendy Becker , Jeannie Lee , Hal Barron , Gavin Screaton |
Address: | 79 New Oxford Street, London, United Kingdom, WC1A 1DG |
Phone: | +44 (0)20 8047 5000 |
Website: | http://www.gsk.com |
Sector: | Pharma and Biotech(LSE) |
Index: | techMARK, FTSE 100, FTSE 350, FTSE All-Share |
Overseas Listings: | BATSLON:GSKL, NYSE:GSK |
ISIN: | GB00BN7SWP63 |
Currency | UK Pounds |
Share Price | 1,448.50p |
Change Today | -14.50p |
% Change | -0.99 % |
52 Week High | 1,812.50p |
52 Week Low | 1,264.00p |
Volume | 7,904,168 |
Shares Issued | 4,109.73m |
Market Cap | £59,530m |
RiskGrade | 129 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 14 |
Sell | 3 |
Strong Sell | 1 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q1 | Q4 | |
Ex-Div | 15-May-25 | 20-Feb-25 |
Paid | 10-Jul-25 | 10-Apr-25 |
Amount | 16.00p | 16.00p |
Time | Volume / Share Price |
16:26 | 0 @ 1,449.00p |
16:26 | 2 @ 1,449.00p |
16:26 | 2 @ 1,449.00p |
16:26 | 0 @ 1,449.00p |
16:26 | 6 @ 1,449.00p |
You are here: research